Shares of Incyte (INCY) climbed 2.51% today on the announcement of positive results from a Phase 2 clinical trial, GEOMETRY mono-1, evaluating MET inhibitor capmatinib in 94 adult patients with advanced non-small cell lung cancer. The company presented the data at the European Society for Medical Oncology meeting in Munich. Licensee Novartis (NVS) has said […]
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.